Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (541-550 of 575) with videos related to

Pageof 58
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Clinical Lung Cancer|November 22, 2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Saiama N Waqar, Mary W Redman, Susanne M Arnold, et al.
The Lancet. Respiratory Medicine|November 17, 2018
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)Nasser K Altorki, Xiaofei Wang, Dennis Wigle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancerMark A Socinski, Robert N Raju, Thomas Stinchcombe, et al.
JAMA Oncology|June 4, 2019
Factors Associated With Age Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, Walker Mainwaring, Timothy A Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLCMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Carcinogenesis|April 7, 2017
Functional variants in DCAF4 associated with lung cancer risk in European populationsHongliang Liu, Zhensheng Liu, Yanru Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, et al.
Pageof 58

Showing results (541-550 of 575) with videos related to

Sort By:
Pageof 58
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Clinical Lung Cancer|November 22, 2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Saiama N Waqar, Mary W Redman, Susanne M Arnold, et al.
The Lancet. Respiratory Medicine|November 17, 2018
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)Nasser K Altorki, Xiaofei Wang, Dennis Wigle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancerMark A Socinski, Robert N Raju, Thomas Stinchcombe, et al.
JAMA Oncology|June 4, 2019
Factors Associated With Age Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, Walker Mainwaring, Timothy A Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLCMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Carcinogenesis|April 7, 2017
Functional variants in DCAF4 associated with lung cancer risk in European populationsHongliang Liu, Zhensheng Liu, Yanru Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, et al.
Pageof 58